ZA200710056B - Lipid construct for delivery of interferon to a mammal - Google Patents

Lipid construct for delivery of interferon to a mammal

Info

Publication number
ZA200710056B
ZA200710056B ZA200710056A ZA200710056A ZA200710056B ZA 200710056 B ZA200710056 B ZA 200710056B ZA 200710056 A ZA200710056 A ZA 200710056A ZA 200710056 A ZA200710056 A ZA 200710056A ZA 200710056 B ZA200710056 B ZA 200710056B
Authority
ZA
South Africa
Prior art keywords
interferon
mammal
delivery
lipid construct
lipid
Prior art date
Application number
ZA200710056A
Other languages
English (en)
Inventor
John R Lau
Blair W Geho
Original Assignee
Sdg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sdg Inc filed Critical Sdg Inc
Publication of ZA200710056B publication Critical patent/ZA200710056B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200710056A 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal ZA200710056B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23

Publications (1)

Publication Number Publication Date
ZA200710056B true ZA200710056B (en) 2009-03-25

Family

ID=39661981

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200710056A ZA200710056B (en) 2005-05-23 2006-05-16 Lipid construct for delivery of interferon to a mammal
ZA200710055A ZA200710055B (en) 2005-05-23 2006-05-16 Lipid construct for delivery of insulin to a mammal

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200710055A ZA200710055B (en) 2005-05-23 2006-05-16 Lipid construct for delivery of insulin to a mammal

Country Status (5)

Country Link
US (1) US20100129428A1 (xx)
JP (1) JP5414270B2 (xx)
KR (1) KR101389226B1 (xx)
CN (2) CN101237854B (xx)
ZA (2) ZA200710056B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271226A1 (en) * 2013-09-30 2016-09-22 Wockhardt Limited Pharmaceutical composition
CN107056802A (zh) * 2017-01-24 2017-08-18 河北百灵威超精细材料有限公司 N‑羟基硫代琥珀酰亚胺生物素酯及其衍生物的制备方法
SG11201908052PA (en) * 2017-03-13 2019-09-27 Sdg Inc Lipid-based nanoparticles with enhanced stability
JP2021509900A (ja) * 2018-01-05 2021-04-08 エスディージー インコーポレイテッド 糖尿病を処置するための脂質ベースのナノ粒子を含む組成物
KR102530032B1 (ko) 2019-09-18 2023-05-09 정원구 반려동물용 현탁액 조성물 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
WO1999059545A1 (en) * 1998-05-19 1999-11-25 Sdg, Inc. Targeted liposomal drug delivery system
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
KR20050083677A (ko) * 2002-09-05 2005-08-26 더 제너럴 하스피탈 코포레이션 변형 아시알로 인터페론 및 그의 용도
US20050026826A1 (en) 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides

Also Published As

Publication number Publication date
KR101389226B1 (ko) 2014-04-25
US20100129428A1 (en) 2010-05-27
CN101237854A (zh) 2008-08-06
ZA200710055B (en) 2009-03-25
CN101237855A (zh) 2008-08-06
JP5414270B2 (ja) 2014-02-12
KR20080043742A (ko) 2008-05-19
CN101237854B (zh) 2013-03-27
JP2009507761A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
EP1883394A4 (en) LIPID CONSTRUCTION FOR ADMINISTRATION OF INSULIN TO A MAMMAL
ZA200900028B (en) Improvements relating to pharmaceutical compositions
ZA200904445B (en) Cyclopamine analogs
EP1883395A4 (en) LIPID CONSTRUCTION FOR THE ADMINISTRATION OF INTERFERON TO A MAMMAL
ZA200710056B (en) Lipid construct for delivery of interferon to a mammal
EP2033643A4 (en) COMPRESSED PREPARATION
GB0621467D0 (en) Improvements relating to residues
GB0616834D0 (en) Improvements to vacuum cleaners
TWM300307U (en) Improved positioning structure of a light-guide
IL207764A0 (en) Antibody to a purified enho1 peptide
EP2109454A4 (en) PHARMACEUTICAL COMPOSITIONS BASED ON GLP-1
GB0600299D0 (en) Way to go
HUE039023T2 (hu) Lipid konstruktok inzulin leadására emlõs számára
TWI318598B (en) Mold structure
PL379202A1 (pl) Świeca w osłonce
GB0607492D0 (en) Improvements to pumps
GB0602393D0 (en) Improvements to combustion
GB0605505D0 (en) Improvements to loudspeakers
GB0623613D0 (en) Improvements relating to barbecues
ZA200904725B (en) GLP-1 Pharmaceutical compositions
GB0607689D0 (en) Improvements relating to gas production
GB0607648D0 (en) Improvements relating to gas production
GB0621288D0 (en) Improvements relating to display devices
TWM300523U (en) Cross-barrier structure of vacuum cleaner
PL369083A1 (pl) Preparat wspomagający w rzucaniu palenia tytoniu